Search

Your search keyword '"Poon, Michelle Limei"' showing total 26 results
Start Over Author "Poon, Michelle Limei"
26 results on '"Poon, Michelle Limei"'

3. Oral Abstract: ABCL-500 Longer Follow-Up Reaffirms Subcutaneous Epcoritamab Induces Deep and Durable Complete Remissions in Patients With Relapsed/Refractory Large B-Cell Lymphoma: Updated Results From the Pivotal EPCORE NHL-1 Trial

Author

Karimi, Yasmin, primary, Ghesquieres, Herve, additional, Jurczak, Wojciech, additional, Cheah, Chan Y., additional, Clausen, Michael Roost, additional, Lugtenburg, Pieternella, additional, Cunningham, David, additional, Do, Young Rok, additional, Lewis, David John, additional, Gasiorowski, Robin, additional, Kim, Tae Min, additional, van der Poel, Marjolein, additional, Poon, Michelle Limei, additional, Feldman, Tatyana, additional, Linton, Kim M., additional, Sureda, Anna, additional, Hutchings, Martin, additional, Stirner, Mariana Cota, additional, Liu, Yan, additional, Kilavuz, Nurgul, additional, Sacchi, Mariana, additional, and Thieblemont, Catherine, additional

Published
2023
Full Text
View/download PDF

4. ABCL-500 Longer Follow-Up Reaffirms Subcutaneous Epcoritamab Induces Deep and Durable Complete Remissions in Patients With Relapsed/Refractory Large B-Cell Lymphoma: Updated Results From the Pivotal EPCORE NHL-1 Trial

Author

Karimi, Yasmin, primary, Ghesquieres, Herve, additional, Jurczak, Wojciech, additional, Cheah, Chan Y., additional, Clausen, Michael Roost, additional, Lugtenburg, Pieternella, additional, Cunningham, David, additional, Do, Young Rok, additional, Lewis, David John, additional, Gasiorowski, Robin, additional, Kim, Tae Min, additional, van der Poel, Marjolein, additional, Poon, Michelle Limei, additional, Feldman, Tatyana, additional, Linton, Kim M., additional, Sureda, Anna, additional, Hutchings, Martin, additional, Stirner, Mariana Cota, additional, Liu, Yan, additional, Kilavuz, Nurgul, additional, Sacchi, Mariana, additional, and Thieblemont, Catherine, additional

Published
2023
Full Text
View/download PDF

5. POSTER: ABCL-500 Longer Follow-Up Reaffirms Subcutaneous Epcoritamab Induces Deep and Durable Complete Remissions in Patients With Relapsed/Refractory Large B-Cell Lymphoma: Updated Results From the Pivotal EPCORE NHL-1 Trial

Author

Karimi, Yasmin, primary, Ghesquieres, Herve, additional, Jurczak, Wojciech, additional, Cheah, Chan Y., additional, Clausen, Michael Roost, additional, Lugtenburg, Pieternella, additional, Cunningham, David, additional, Do, Young Rok, additional, Lewis, David John, additional, Gasiorowski, Robin, additional, Kim, Tae Min, additional, van der Poel, Marjolein, additional, Poon, Michelle Limei, additional, Feldman, Tatyana, additional, Linton, Kim M., additional, Sureda, Anna, additional, Hutchings, Martin, additional, Stirner, Mariana Cota, additional, Liu, Yan, additional, Kilavuz, Nurgul, additional, Sacchi, Mariana, additional, and Thieblemont, Catherine, additional

Published
2023
Full Text
View/download PDF

6. ABCL-422 Subcutaneous Epcoritamab in Patients With Relapsed or Refractory Large B-Cell Lymphoma (EPCORE NHL-1): Pivotal Results from a Phase 2 Study

Author

Thieblemont, Catherine, Phillips, Tycel, Ghesquieres, Herve, Cheah, Chan Y., Clausen, Michael Roost, Cunningham, David, Do, Young Rok, Feldman, Tatyana, Gasiorowski, Robin, Jurczak, Wojciech, Kim, Tae Min, Lewis, David John, van der Poel, Marjolein, Poon, Michelle Limei, Doerr, Thomas, Kilavuz, Nurgul, Chen, Menghui, Sacchi, Mariana, Elliott, Brian, Hutchings, Martin, and Lugtenburg, Pieternella

Published
2022
Full Text
View/download PDF

7. Clinical features and prognostic outcomes of angioimmunoblastic T cell lymphoma in an Asian multicenter study

Author

Chang, Esther Wei Yin, primary, Yang, Valerie Shiwen, additional, Ong, Shin Yeu, additional, Kang, Hilda Xueqi, additional, Lim, Boon Yee, additional, de Mel, Sanjay, additional, Ng, Esther Ka Yan, additional, Poon, Michelle Limei, additional, Tan, Ya Hwee, additional, Chiang, Jianbang, additional, Poon, Eileen, additional, Somasundaram, Nagavalli, additional, Farid, Mohamad, additional, Tang, Tiffany, additional, Tao, Miriam, additional, Khoo, Lay Poh, additional, Cheng, Chee Leong, additional, Huang, Dachuan, additional, Ong, Choon Kiat, additional, Lim, Soon Thye, additional, and Chan, Jason Yongsheng, additional

Published
2023
Full Text
View/download PDF

8. Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma:Dose Expansion in a Phase I/II Trial

Author

Thieblemont, Catherine, Phillips, Tycel, Ghesquieres, Herve, Cheah, Chan Y, Clausen, Michael Roost, Cunningham, David, Do, Young Rok, Feldman, Tatyana, Gasiorowski, Robin, Jurczak, Wojciech, Kim, Tae Min, Lewis, David John, van der Poel, Marjolein, Poon, Michelle Limei, Cota Stirner, Mariana, Kilavuz, Nurgul, Chiu, Christopher, Chen, Menghui, Sacchi, Mariana, Elliott, Brian, Ahmadi, Tahamtan, Hutchings, Martin, Lugtenburg, Pieternella J, Thieblemont, Catherine, Phillips, Tycel, Ghesquieres, Herve, Cheah, Chan Y, Clausen, Michael Roost, Cunningham, David, Do, Young Rok, Feldman, Tatyana, Gasiorowski, Robin, Jurczak, Wojciech, Kim, Tae Min, Lewis, David John, van der Poel, Marjolein, Poon, Michelle Limei, Cota Stirner, Mariana, Kilavuz, Nurgul, Chiu, Christopher, Chen, Menghui, Sacchi, Mariana, Elliott, Brian, Ahmadi, Tahamtan, Hutchings, Martin, and Lugtenburg, Pieternella J

Abstract

PURPOSE: Epcoritamab is a subcutaneously administered CD3xCD20 T-cell-engaging, bispecific antibody that activates T cells, directing them to kill malignant CD20+ B cells. Single-agent epcoritamab previously demonstrated potent antitumor activity in dose escalation across B-cell non-Hodgkin lymphoma subtypes.PATIENTS AND METHODS: In the dose-expansion cohort of a phase I/II study (ClinicalTrials.gov identifier: NCT03625037), adults with relapsed or refractory CD20+ large B-cell lymphoma and at least two prior therapy lines (including anti-CD20 therapies) received subcutaneous epcoritamab in 28-day cycles (once weekly step-up doses in weeks 1-3 of cycle 1, then full doses once weekly through cycle 3, once every 2 weeks in cycles 4-9, and once every 4 weeks in cycle 10 and thereafter) until disease progression or unacceptable toxicity. The primary end point was overall response rate by the independent review committee.RESULTS: As of January 31, 2022, 157 patients were treated (median age, 64 years [range, 20-83]; median of three [range, 2-11] prior therapy lines; primary refractory disease: 61.1%; prior chimeric antigen receptor (CAR) T-cell exposure: 38.9%). At a median follow-up of 10.7 months, the overall response rate was 63.1% (95% CI, 55.0 to 70.6) and the complete response rate was 38.9% (95% CI, 31.2 to 46.9). The median duration of response was 12.0 months (among complete responders: not reached). Overall and complete response rates were similar across key prespecified subgroups. The most common treatment-emergent adverse events were cytokine release syndrome (49.7%; grade 1 or 2: 47.1%; grade 3: 2.5%), pyrexia (23.6%), and fatigue (22.9%). Immune effector cell-associated neurotoxicity syndrome occurred in 6.4% of patients with one fatal event.CONCLUSION: Subcutaneous epcoritamab resulted in deep and durable responses and manageable safety in highly refractory patients with large B-cell lymphoma, including those with prior CAR T-cell e

Published
2023

9. Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial

Author

Thieblemont, Catherine, Karimi, Yasmin H., Ghesquieres, Herve, Cheah, Chan Y., Clausen, Michael Roost, Cunningham, David, Jurczak, Wojciech, Do, Young Rok, Gasiorowski, Robin, Lewis, David John, Kim, Tae Min, van der Poel, Marjolein, Poon, Michelle Limei, Feldman, Tatyana, Linton, Kim M., Sureda, Anna, Hutchings, Martin, Dinh, Minh H., Kilavuz, Nurgul, Soong, David, Mark, Thomas, Sacchi, Mariana, Phillips, Tycel, and Lugtenburg, Pieternella J.

Abstract

Primary results (median follow-up, 10.7 months) from the pivotal EPCORE®NHL-1 study in relapsed or refractory (R/R) large B-cell lymphoma (LBCL) demonstrated deep, durable responses with epcoritamab, a CD3xCD20 bispecific antibody, when used as monotherapy. We report long-term efficacy and safety results in patients with LBCL (N= 157; 25.1-month median follow-up). As of April 21, 2023, overall response rate was 63.1% and complete response (CR) rate was 40.1%. Estimated 24-month progression-free survival (PFS) and overall survival (OS) rates were 27.8% and 44.6%, respectively. An estimated 64.2% of complete responders remained in CR at 24 months. Estimated 24-month PFS and OS rates among complete responders were 65.1% and 78.2%, respectively. Of 119 minimal residual disease (MRD)-evaluable patients, 45.4% had MRD negativity, which correlated with longer PFS and OS. CR rates were generally consistent across predefined subgroups: 36% prior chimeric antigen receptor (CAR) T-cell therapy, 32% primary refractory disease, and 37% International Prognostic Index ≥3. The most common treatment-emergent adverse events were cytokine release syndrome (51.0%), pyrexia (24.8%), fatigue (24.2%), and neutropenia (23.6%). These results underscore the long-term benefit of epcoritamab for treating R/R LBCL with deep responses across subgroups, including patients with hard-to-treat disease and expected poor prognosis (ClinicalTrials.gov Registration: NCT03625037).

Published
2024
Full Text
View/download PDF

10. Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial

Author

Thieblemont, Catherine, primary, Phillips, Tycel, additional, Ghesquieres, Herve, additional, Cheah, Chan Y., additional, Clausen, Michael Roost, additional, Cunningham, David, additional, Do, Young Rok, additional, Feldman, Tatyana, additional, Gasiorowski, Robin, additional, Jurczak, Wojciech, additional, Kim, Tae Min, additional, Lewis, David John, additional, van der Poel, Marjolein, additional, Poon, Michelle Limei, additional, Cota Stirner, Mariana, additional, Kilavuz, Nurgul, additional, Chiu, Christopher, additional, Chen, Menghui, additional, Sacchi, Mariana, additional, Elliott, Brian, additional, Ahmadi, Tahamtan, additional, Hutchings, Martin, additional, and Lugtenburg, Pieternella J., additional

Published
2022
Full Text
View/download PDF

11. A Non-Coding Variant in LOC105371512 Confers Susceptibility to Bleomycin-Induced Lung Injury

Author

Lee, Joanne, primary, Tabatabaeian, Hossein, additional, Poon, Michelle Limei, additional, Somasundaram, Nagavalli, additional, Xin, Liu, additional, Yuen, Yi Ching, additional, Teoh, Chia Meng, additional, Yan, Benedict, additional, Chan, Esther Hian Li, additional, Chee, Yen Lin, additional, De Mel, Sanjay, additional, Zhang, Bin, additional, Chew, Xiao Hong, additional, Tang, Tiffany, additional, Khor, Chiea Chuen, additional, Ngeow, Joanne Yuen Yie, additional, Ong, Choon Kiat, additional, Lim, Soon Thye, additional, Chng, Wee Joo, additional, Tai, E Shyong, additional, Ngiam, Kee Yuan, additional, Lee, Soo Chin, additional, Goh, Boon Cher, additional, Jeyasekharan, Anand Devaprasath D., additional, Tay, Yvonne, additional, and Aminkeng, Folefac, additional

Published
2022
Full Text
View/download PDF

12. Haploidentical Transplant Using Selective Ex-Vivo Tcrαβ Depleting and Memory T Cell Add-Back Results in More Favorable Gvhd-Free /Relapse Free Survival (GRFS) As Compared to Post-Transplant Cyclophosphamide for Adults with Hematological Malignancies - a Comparative Analysis of 170 Patients in a Multicenter Study in Singapore

Author

Wei Teik, Victor Ling, primary, Linn, Yeh Ching, additional, Poon, Michelle Limei, additional, Quek, Jeffrey, additional, Tan, Lip Kun, additional, Lim, Zi Yi, additional, Diong, Colin Phipps, additional, Vellayappan, Balamurugan, additional, Lee, Joanne, additional, Hwang, William YK, additional, Than, Hein, additional, Ho, Aloysius YL, additional, Wu, Ian, additional, Boo, Yang Liang, additional, Soh, Teck Guan, additional, Gan, Gina, additional, Loh, Yvonne Su Ming, additional, Koh, Yin Jie, additional, and Koh, Liang Piu, additional

Published
2022
Full Text
View/download PDF

13. Haploidentical Hematopoietic Cell Transplantation of Ex Vivo Tcrαβ-Depleted Grafts with CD45RA-Depleted Memory T Cell Add-Back Reduces Chronic Graft-Versus-Host Disease and Results in Favourable Gvhd-Relapse Free Survival: 5-Year Follow-up of 107 Patients Treated in a Multicenter Study in Singapore

Author

Koh, Liang Piu, primary, Poon, Michelle Limei, additional, Quek, Jeffrey, additional, Tan, Lip Kun, additional, Bhattacharyya, Rajat, additional, Seng, Michaela Su-Fern, additional, Lim, Zi Yi, additional, Tan, Poh Lin, additional, Diong, Colin Phipps, additional, Vellayappan, Balamurugan, additional, Tan, Ah Moy, additional, Lee, Joanne, additional, Hwang, William Y.K., additional, Than, Hein, additional, Ho, Aloysius, additional, Wu, Ian Q.H., additional, Boo, Yang Liang, additional, Loh, Yvonne S.M., additional, Soh, Teck Guan, additional, Gan, Gina, additional, Yeoh, Kheng Wei, additional, Looi, Wen Shen, additional, Ho, Bryan S.H., additional, Koh, Yin Jie, additional, Leung, Wing Y., additional, and Linn, Yeh Ching, additional

Published
2022
Full Text
View/download PDF

14. Epcoritamab Monotherapy Provides Deep and Durable Responses Including Minimal Residual Disease (MRD) Negativity: Novel Subgroup Analyses in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Author

Phillips, Tycel, primary, Thieblemont, Catherine, additional, Ghesquieres, Herve, additional, Cheah, Chan Y., additional, Clausen, Michael Roost, additional, Cunningham, David, additional, Do, Young Rok, additional, Feldman, Tatyana A., additional, Gasiorowski, Robin, additional, Jurczak, Wojciech, additional, Kim, Tae Min, additional, Lewis, David John, additional, van der Poel, Marjolein, additional, Poon, Michelle Limei, additional, Kilavuz, Nurgul, additional, Cota Stirner, Mariana, additional, Soong, David, additional, Chiu, Christopher, additional, Chen, Menghui, additional, Sacchi, Mariana, additional, Elliot, Brian, additional, Hutchings, Martin, additional, and Lugtenburg, Pieternella, additional

Published
2022
Full Text
View/download PDF

15. Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2

Author

Kim, Won-Seog, primary, Kim, Tae Min, additional, Cho, Seok-Goo, additional, Jarque, Isidro, additional, Iskierka-Jażdżewska, Elżbieta, additional, Poon, Michelle Limei, additional, Prince, H. Miles, additional, Oh, Sung Yong, additional, Lim, Francesca, additional, Carpio, Cecilia, additional, Tan, Tran-Der, additional, Ayyappan, Sabarish, additional, Gutierrez, Antonio, additional, Li, Jingjin, additional, Ufkin, Melanie, additional, Zhu, Min, additional, Chaudhry, Aafia, additional, Mohamed, Hesham, additional, Ambati, Srikanth R., additional, and Walewski, Jan, additional

Published
2022
Full Text
View/download PDF

16. Sequential Use of Flamsa, FLAG, CLAG or TEC-Based Conditioning Regimen Followed By Allogeneic Hematopoietic Transplantation Results in Favorable Outcome for High Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myeloproliferative Neoplasia Patients: 15 Year Follow-up of the Multicenter Study in Singapore

Author

Chong, Lip Leong, primary, Boo, Yang Liang, additional, Koh, Yin Jie, additional, Lee, Joanne, additional, Poon, Michelle Limei, additional, Quek, Jeffrey, additional, Than, Hein, additional, Linn, Yeh Ching, additional, Hwang, William YK, additional, Ho, Aloysius YL, additional, Tan, Lip Kun, additional, and Koh, Liang Piu, additional

Published
2022
Full Text
View/download PDF

17. Odronextamab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Grade 1-3a: Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2

Author

Kim, Tae Min, primary, Taszner, Michal, additional, Cho, Seok-Goo, additional, Novelli, Silvana, additional, Le Gouill, Steven, additional, Poon, Michelle Limei, additional, Villasboas, Jose C., additional, Champion, Rebecca, additional, Bachy, Emmanuel, additional, Guidez, Stéphanie, additional, Alonso Alonso, Aránzazu, additional, Jagadeesh, Deepa, additional, Merli, Michele, additional, Tucker, David, additional, Cai, Jingxian, additional, Leite De Oliveira, Carolina, additional, Zhu, Min, additional, Chaudhry, Aafia, additional, Mohamed, Hesham, additional, Ambati, Srikanth R., additional, and Luminari, Stefano, additional

Published
2022
Full Text
View/download PDF

18. Poster: ABCL-422 Subcutaneous Epcoritamab in Patients With Relapsed or Refractory Large B-Cell Lymphoma (EPCORE NHL-1): Pivotal Results from a Phase 2 Study

Author

Thieblemont, Catherine, primary, Phillips, Tycel, additional, Ghesquieres, Herve, additional, Cheah, Chan Y., additional, Clausen, Michael Roost, additional, Cunningham, David, additional, Do, Young Rok, additional, Feldman, Tatyana, additional, Gasiorowski, Robin, additional, Jurczak, Wojciech, additional, Kim, Tae Min, additional, Lewis, David John, additional, van der Poel, Marjolein, additional, Poon, Michelle Limei, additional, Doerr, Thomas, additional, Kilavuz, Nurgul, additional, Chen, Menghui, additional, Sacchi, Mariana, additional, Elliott, Brian, additional, Hutchings, Martin, additional, and Lugtenburg, Pieternella, additional

Published
2022
Full Text
View/download PDF

19. Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial.

Author

Thieblemont, Catherine, Phillips, Tycel, Ghesquieres, Herve, Cheah, Chan Y., Clausen, Michael Roost, Cunningham, David, Do, Young Rok, Feldman, Tatyana, Gasiorowski, Robin, Jurczak, Wojciech, Kim, Tae Min, Lewis, David John, van der Poel, Marjolein, Poon, Michelle Limei, Cota Stirner, Mariana, Kilavuz, Nurgul, Chiu, Christopher, Chen, Menghui, Sacchi, Mariana, and Elliott, Brian

Published
2023
Full Text
View/download PDF

21. Co-Expression of C-MYC/BCL2 Is Associated with Inferior Survival Outcomes in Relapsed/Refractory Diffuse Large B-Cell Lymphoma after Autologous Stem Cell Transplantation - a Nationwide Retrospective Analysis in Singapore

Author

Tan, Jing Yuan, Wei Teik, Victor Ling, Krisnadi, Cindy, Ng, Lawrence Cheng Kiat, Tan, Melinda Si Yun, Grigoropoulos, Nicholas Francis, Ong, Shin Yeu, Nagarajan, Chandramouli, Quek, Jeffrey Kim Siang, Than, Hein, Lee, Joanne Shu Xian, Chan, Esther Hian Li, Tan, Lip Kun, Hwang, William Ying Khee, Goh, Yeow Tee, Linn, Yeh Ching, Koh, Liang Piu, Ho, Aloysius Yew Leng, Inng Lim, Francesca Lorraine Wei, Poon, Michelle Limei, and Chen, Yunxin

Published
2023
Full Text
View/download PDF

22. A Non-Coding Variant in LOC105371512Confers Susceptibility to Bleomycin-Induced Lung Injury

Author

Lee, Joanne, Tabatabaeian, Hossein, Poon, Michelle Limei, Somasundaram, Nagavalli, Xin, Liu, Yuen, Yi Ching, Teoh, Chia Meng, Yan, Benedict, Chan, Esther Hian Li, Chee, Yen Lin, De Mel, Sanjay, Zhang, Bin, Chew, Xiao Hong, Tang, Tiffany, Khor, Chiea Chuen, Ngeow, Joanne Yuen Yie, Ong, Choon Kiat, Lim, Soon Thye, Chng, Wee Joo, Tai, E Shyong, Ngiam, Kee Yuan, Lee, Soo Chin, Goh, Boon Cher, Jeyasekharan, Anand Devaprasath D., Tay, Yvonne, and Aminkeng, Folefac

Published
2022
Full Text
View/download PDF

23. Disease Risk Index (DRI) and Conditioning Regimen Based Risk Stratification of Outcome Among Adults with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Cell Transplantation

Author

Yip, Alexander, primary, Tai, Bee Choo, additional, Linn, Yeh Ching, additional, Tan, Lip Kun, additional, Poon, Michelle Limei, additional, Lim, Ziyi, additional, Tan, Belinda, additional, Lim, Yelly, additional, Soh, Teck-Guan, additional, Del Rosario, Davanaliz R., additional, Hwang, William Y.K., additional, and Koh, Liang Piu, additional

Published
2016
Full Text
View/download PDF

24. Haploidentical Transplant Using Selective Ex-VivoTcrαβ Depleting and Memory T Cell Add-Back Results in More Favorable Gvhd-Free /Relapse Free Survival (GRFS) As Compared to Post-Transplant Cyclophosphamide for Adults with Hematological Malignancies - a Comparative Analysis of 170 Patients in a Multicenter Study in Singapore

Author

Wei Teik, Victor Ling, Linn, Yeh Ching, Poon, Michelle Limei, Quek, Jeffrey, Tan, Lip Kun, Lim, Zi Yi, Diong, Colin Phipps, Vellayappan, Balamurugan, Lee, Joanne, Hwang, William YK, Than, Hein, Ho, Aloysius YL, Wu, Ian, Boo, Yang Liang, Soh, Teck Guan, Gan, Gina, Loh, Yvonne Su Ming, Koh, Yin Jie, and Koh, Liang Piu

Published
2022
Full Text
View/download PDF

26. Double Unit Umbilical Cord Blood Transplant for Adults with Acute Leukemia and Myelodysplastic Syndrome Results in Comparable Outcome As Matched Sibling or Unrelated Donor Transplant Only after Myeloablative Conditioning but Not Reduced Intensity Conditio

Author

Poon, Michelle Limei, Linn, Yeh Ching, Lim, Ziyi, Ho, Aloysius, Tan, Lip Kun, Soh, Teck Guan, Heng, Kk, Tan, Belinda, - Yelly, Lee, Jing Jing, Ng, Heng Joo, Hwang, William Y.K., and Koh, Liang Piu

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results